SecBot SecBot
SECBOTREPLAY Home › Report › PALI

PALI · Palisade Bio issued 1.54 million shares to an affiliate of Iterative…

PALISADE BIO, INC. · 8-K filed Apr 2, 2026 at 08:34 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Apr 2, 2026 at 08:34 ET

Palisade Bio issued 1.54 million shares to an affiliate of Iterative Health for $3.0 million to support a clinical trial partnership for its ulcerative colitis drug PALI-2108. The company also entered into a master services agreement with Iterative Health to accelerate patient enrollment in the upcoming Phase 2 study.

  • Palisade Bio issued 1,536,885 shares of common stock to an affiliate of Iterative Health for $3.0 million ($1.952 per share)
  • Proceeds support collaboration with Iterative Health to expedite patient enrollment in the Phase 2 study of PALI-2108 for moderate to severe ulcerative colitis
  • The share issuance was conducted under a private placement exempt from registration under Section 4(a)(2) of the Securities Act
  • The transaction represents approximately 4.9% of Palisade Bio's current market cap of $312M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access